Moreover, Becker et al. described how tumor-produced CSF-1 and IL-6 can contribute to switching DCs from an anti-tumor phenotype to DC3s, which induce weak tumor antigen-specific CD8+ T cell activation (Figure 2). This evidence concerns the gene IL6 and neoplasm.